Blood Plasma Derivatives Market Insights And Forecast 2025-2030 - Grifols, SK Plasma, And Fusion Health Care Lead The Competition
Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9%< ...
EURACTIV20h
Belgium’s new government unveils wide-ranging health reform agenda, including key pharma measures
The ambitious plans aim to secure medicine supply, accelerate innovation, strengthen clinical research, and reinforce IP ...
PharmiWeb1d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Can the EU safeguard critical medicines?
Drug shortages are an old problem, but over the past few years they have hit record levels. View on euronews ...
EuropaWire2d
AstraZeneca’s Imfinzi Recommended for EU Approval as Breakthrough Treatment for Limited-Stage Small Cell Lung Cancer
AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...
Commission cuts feedback amid races to push Critical Medicines Act
The EU executive is expected to push ahead with an extremely streamlined timeline for a key piece of health legislation, ...
Le Lézard6d
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE ... Meloxicam is a COX-2 preferential non-steroidal anti-inflammatory drug (NSAID) and rizatriptan is a 5-HT 1B/1D agonist. SYMBRAVO is designed to provide ...
Inverse6d
Ozempic And Other GLP-1s Show Promise With 42 Conditions — But There Are Still Big Risks
Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...